Shares of Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.78 and traded as high as $1.23. Synlogic shares last traded at $1.23, with a volume of 55,117 shares trading hands.
Synlogic Price Performance
The firm has a market capitalization of $15.07 million, a PE ratio of -4.73 and a beta of 0.48. The business’s 50-day moving average price is $0.78 and its 200-day moving average price is $0.69.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of SYBX. DRW Securities LLC purchased a new stake in shares of Synlogic in the fourth quarter valued at about $27,000. Citadel Advisors LLC purchased a new position in shares of Synlogic during the third quarter worth about $49,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Synlogic by 116.7% during the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock worth $96,000 after buying an additional 46,117 shares during the last quarter. 63.40% of the stock is owned by hedge funds and other institutional investors.
Synlogic Company Profile
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
See Also
- Five stocks we like better than Synlogic
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
- AI Cold War Catches Light: Federal Friction in the Server Rack
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
